Citation Impact
Citing Papers
Factors Associated With Severe Late Toxicity After Concurrent Chemoradiation for Locally Advanced Head and Neck Cancer: An RTOG Analysis
2008 Standout
Evaluation of the Houston biochemical relapse definition in men treated with prolonged neoadjuvant and adjuvant androgen ablation and assessment of follow-up lead-time bias
2003
Head and neck squamous cell carcinoma
2020 Standout
Radiation Dose–Volume Effects in the Larynx and Pharynx
2010
EGFR Antagonists in Cancer Treatment
2008 Standout
The FGF family: biology, pathophysiology and therapy
2009 Standout
Targeting epidermal growth factor receptor in head and neck cancer
2002
Global Cancer Statistics, 2002
2005 Standout
Radiation Doses to Structures Within and Adjacent to the Larynx are Correlated With Long-Term Diet- and Speech-Related Quality of Life
2007
Phase III Multi-Institutional Trial of Adjuvant Chemotherapy With Paclitaxel, Estramustine, and Oral Etoposide Combined With Long-Term Androgen Suppression Therapy and Radiotherapy Versus Long-Term Androgen Suppression Plus Radiotherapy Alone for High-Risk Prostate Cancer: Preliminary Toxicity Analysis of RTOG 99-02
2008
Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer
2003
Use of doping agents, particularly anabolic steroids, in sports and society
2008 Standout
The use of hormonal therapy with radiotherapy for prostate cancer: analysis of prospective randomised trials
2004
Is dehydroepiandrosterone a hormone?
2005
Screening decreases prostate cancer mortality: 11‐year follow‐up of the 1988 Quebec prospective randomized controlled trial
2004
Initial decline in hemoglobin during neoadjuvant hormonal therapy predicts for early prostate specific antigen failure following radiation and hormonal therapy for patients with intermediate and high‐risk prostate cancer
2002
Head and neck cancer
2008 Standout
The Effect of Palifermin on Chemotherapyand Radiation Therapy–Induced Mucositis: A Review of the Current Literature
2007
Nimotuzumab: a novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicity
2009
EGF–ERBB signalling: towards the systems level
2006 Standout
Comparison of Conventional-Dose vs High-Dose Conformal Radiation Therapy in Clinically Localized Adenocarcinoma of the Prostate
2005 Standout
Biochemical outcome for hormone-naive patients with Gleason score 3+4 versus 4+3 prostate cancer undergoing permanent prostate brachytherapy
2002
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
2005 Standout
Antibody therapy of cancer
2012 Standout
Unnecessary laryngeal irradiation in the IMRT era
2004
The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma
2015 Standout
EAU Guidelines on Prostate Cancer
2007 Standout
Double-blind randomized phase II study of hyperbaric oxygen in patients with radiation-induced brachial plexopathy
2001
Twenty-Five-Year Follow-up of a Randomized Trial Comparing Radical Mastectomy, Total Mastectomy, and Total Mastectomy Followed by Irradiation
2002 Standout
Radical Prostatectomy versus Watchful Waiting in Early Prostate Cancer
2011 Standout
Testosterone recovery following prolonged adjuvant androgen ablation for prostate carcinoma
2002
A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy
2011
Assessment of voice, speech, and related quality of life in advanced head and neck cancer patients 10-years+ after chemoradiotherapy
2016
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
2010 Standout
Hyperbaric oxygen: its uses, mechanisms of action and outcomes
2004 Standout
An Update of the Phase III Trial Comparing Whole Pelvic to Prostate Only Radiotherapy and Neoadjuvant to Adjuvant Total Androgen Suppression: Updated Analysis of RTOG 94-13, With Emphasis on Unexpected Hormone/Radiation Interactions
2007
Trends in prostate cancer mortality among black men and white men in the United States
2003
Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome
2005 Standout
Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference
2006 Standout
Axillary lymph nodes and breast cancer. A review
1995
Adverse Effects of Androgen Deprivation Therapy and Strategies to Mitigate Them
2014 Standout
EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent—Update 2013
2013 Standout
Lymphatic Mapping and Sentinel Node Biopsy in the Patient With Breast Cancer
1996 Standout
Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement
2012 Standout
Monoclonal Antibodies for Cancer Therapy
2012 StandoutNobel
ICRP PUBLICATION 118: ICRP Statement on Tissue Reactions and Early and Late Effects of Radiation in Normal Tissues and Organs — Threshold Doses for Tissue Reactions in a Radiation Protection Context
2012 Standout
Postmastectomy Radiotherapy: Clinical Practice Guidelines of the American Society of Clinical Oncology*
2001
Androgen Suppression Plus Radiation Versus Radiation Alone for Patients With Stage D1/Pathologic Node-Positive Adenocarcinoma of the Prostate: Updated Results Based on National Prospective Randomized Trial Radiation Therapy Oncology Group 85-31
2005
Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial
2002 Standout
Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials
2014 Standout
Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer
2006
Phase III Trial Comparing Whole-Pelvic Versus Prostate-Only Radiotherapy and Neoadjuvant Versus Adjuvant Combined Androgen Suppression: Radiation Therapy Oncology Group 9413
2003
Phase III Trial of Long-Term Adjuvant Androgen Deprivation After Neoadjuvant Hormonal Cytoreduction and Radiotherapy in Locally Advanced Carcinoma of the Prostate: The Radiation Therapy Oncology Group Protocol 92–02
2003
Works of V.M. Venkatesan being referenced
Vocal Function Following Radiation for Non‐Laryngeal Versus Laryngeal Tumors of the Head and Neck
2001
Hyperbaric Oxygen Corrects Sacral Plexopathy Due to Osteoradionecrosis Appearing 15 Years After Pelvic Irradiation
1999
Effects of Head and Neck Radiation Therapy on Vocal Function
2001
Loccregional reciimence and extranodal extension in patients receiving systemic therapy for axillary node positive breast cancer
1993
RTOG protocol 92-02: A phase III trial of the use of long term total androgen suppression following neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate
2000
A phase I dose escalation study of a humanized monoclonal antibody to EGFR (hR3) in patients with locally advanced squamous cell cancer of the head and neck (SCCHN) treated with radiotherapy
2002
A phase I/II trial of escalating doses of recombinant human keratinocyte growth factor (rHuKGF) in head & neck cancer (HNC) patients receiving radiotherapy (RT) with concurrent chemotherapy (CCT)
2001
22
2006